Table 4 |
|||||||||||||
|
Individual course of disease of BM patients |
|||||||||||||
|
Patient |
MSKCC risk group |
ECOG performance status at diagnosis of BM |
Extracerebral metastatic site |
TX prior first TA |
Time from primary metastasis to BM (months) |
BM-TX |
CNS recurrence during/after TA |
First TA |
Best Response |
PFS |
Following TX lines |
OS |
Progressing metastatic site leading to death |
|
|
|||||||||||||
|
1 |
fav |
0 |
Lung |
Cytokines |
0 |
surg |
no |
SU |
CR |
24.2 |
Ongoing |
24.2 |
non progressing and alive |
|
|
|||||||||||||
|
2 |
interm |
0 |
Lung |
Cytokines, Capecitabin |
45 |
surg |
no |
Beva |
SD |
8.7 |
SU Soraf Tems Tems+Beva |
46.9 |
non progressing and alive |
|
|
|||||||||||||
|
3 |
interm |
1 |
lung, LN |
no |
0 |
surg, WBRT |
no |
SU |
SD |
8.5 |
ongoing |
8.5 |
non progressing and alive |
|
|
|||||||||||||
|
4 |
interm |
1 |
lung, other |
Cytokines |
72 |
SR |
no |
Beva |
SD |
21.6 |
SU, Tems |
36.9 |
lung, liver |
|
|
|||||||||||||
|
5 |
fav |
0 |
liver, bone, other |
Cytokines, Navelbine |
27 |
WBRT, SR |
yes (progression in lesion size) |
Soraf |
PD |
2.6 |
SU |
13.42 |
lung. |
|
|
|||||||||||||
|
6 |
interm |
1 |
other |
no |
0 |
SR, WBRT |
yes (progression in lesion size) |
SU |
PD |
3.4 |
Tems, Beva +Interferon |
10.16 |
Liver |
|
|
|||||||||||||
|
7 |
interm |
0 |
Ln |
no |
0 |
WBRT |
no |
SU |
PR |
3.26 |
Soraf |
18.82 |
non progressing and alive |
|
|
|||||||||||||
|
8 |
interm |
1 |
lung |
no |
0 |
Surg, SR |
no |
SU |
SD |
12.1 |
SU |
40.6 |
non progressing and alive |
|
|
|||||||||||||
|
9 |
interm |
1 |
lung, liver, other |
no |
0 |
SR |
no |
Tems |
SD |
6.3 |
no |
6.3 |
liver, lung |
|
|
|||||||||||||
|
10 |
interm |
0 |
lung, ln |
no |
8 |
WBRT |
no |
Soraf |
PR |
10.9 |
no |
10.9 |
Lung |
|
|
|||||||||||||
|
11 |
interm |
0 |
lung, other |
Cytokines, Navelbine |
14 |
Surg,WBRT |
yes (relapse of resected lesion and new lesions) |
SU |
SD |
3.8 |
no |
3.8 |
cranial vertebral fractures |
|
|
|||||||||||||
|
12 |
poor |
2 |
bone |
no |
0 |
WBRT |
No |
SU |
SD |
6.7 |
no |
6.7 |
Lung |
|
|
|||||||||||||
|
MSKCC = Memorial Sloan-Kettering Center Center fav = favourable risk interm = intermediate risk poor = poor risk ECOG = Eastern Cooperative Oncology Group TX = treatment TA = targeted agent BM = brain metastasis SR = stereotactic radiation WBRT = whole brain radiation therapy Surg = surgery SU = Sunitinib Soraf = Sorafenib Tems = Temsirolimus Beva = Bevacizumab CR = complete remission PR = partial remission SD = stable disease PD = progressive disease PFS = progression free survival OS = overall survival |
|||||||||||||
|
Vogl et al. BMC Cancer 2010 10:480 doi:10.1186/1471-2407-10-480 |
|||||||||||||
